New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 14, 2017 – The FDA approved Mvasi (bevacizumab-awwb), Amgen’s biosimilar to Genentech’s Avastin® (bevacizumab), for the treatment of multiple types of cancer.
Download PDF
Return to publications
